

U.S. National Library of Medicine National Center for Biotechnology Information **NLM Citation:** Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-. Tagraxofusp. [Updated 2019 Jan 7]. **Bookshelf URL:** https://www.ncbi.nlm.nih.gov/books/



# Tagraxofusp

Revised: January 7, 2019.

CASRN: 2055491-00-2

# **Drug Levels and Effects**

# Summary of Use during Lactation

No information is available on the use of tagraxofusp during breastfeeding. The manufacturer recommends that breastfeeding be discontinued during tagraxofusp therapy and for 1 week after the final dose.

## **Drug Levels**

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

## **Effects in Breastfed Infants**

Relevant published information was not found as of the revision date.

#### **Effects on Lactation and Breastmilk**

Relevant published information was not found as of the revision date.

# **Substance Identification**

#### **Substance Name**

Tagraxofusp

# **CAS Registry Number**

2055491-00-2

**Disclaimer:** Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.

## **Drug Class**

Breastfeeding

Lactation

Antineoplastic Agents

**Recombinant Fusion Proteins**